Golimumab biosimilar ( Alvotech)

戈利木单抗生物类似药 ( Alvotech)

Report date: 2025/11/10 15:45:59

Base Information

Drug NameGolimumab biosimilar ( Alvotech)
Drug Alias NameGobivazAVT05AV-T05
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsAxial SpondyloarthritisInflammationColitis, Ulcerative +[6] 
Global Approved IndicationsAxial SpondyloarthritisColitis, UlcerativeArthritis, Rheumatoid +[5] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited Kingdom
Original Approved Date2025/11/06
Country/TerritoryBulgariaNew ZealandUnited Kingdom +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesAlvotech Swiss Ag
China Registration ClassN/A

Develop Information

Active CompaniesAlvotech Swiss AgAdvanz Pharma Ltd
Inactive CompaniesN/A
Active IndicationsAxial SpondyloarthritisInflammationColitis, Ulcerative +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A